|Day Low/High||29.50 / 30.90|
|52 Wk Low/High||16.00 / 45.96|
Merger to result in NASDAQ-listed biopharmaceutical company whose lead asset is a novel Phase 3-ready, oral and intravenous antibiotic drug candidate designed to address the treatment needs of patients with serious community-acquired bacterial infections.
Company also announces the appointment of Matthew M. Loar to the Transcept Board of Directors
These under-$10 stocks look poised to trade higher from current levels.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Investors eyeing a purchase of Transcept Pharmaceuticals Inc stock, but tentative about paying the going market price of $2.97/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2014 put at the $2.50 strike, which has a bid at the time of this writing of 30 cents.
FDA-mandated zolpidem dosage reduction for bedtime products such as Ambien (5 mg and 10 mg tablets) and Ambien CR (6.25 mg and 12.5 mg tablets) does not affect IntermezzoÂ® (zolpidem tartrate 1.75 mg and 3.5 mg sublingual tablets) C-IV dosing
Call Scheduled for Tuesday, November 27, 2012 at 8:30 a.m. ET